Raras
Buscar doenças, sintomas, genes...
Doença linfoproliferativa associada a vírus Epstein-Barr
ORPHA:289644DOENÇA RARA

É um grupo de doenças caracterizadas pela multiplicação descontrolada de células B, T ou NK (tipos de células de defesa), que foram infectadas pelo vírus Epstein-Barr. A forma como a doença se manifesta e sua gravidade dependem da imunidade da pessoa e de fatores do próprio vírus. A persistência viral nessas células pode causar desde um crescimento celular simples e reativo até tipos agressivos de câncer como linfomas e leucemias, cada um com características clínicas e patológicas únicas.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

É um grupo de doenças caracterizadas pela multiplicação descontrolada de células B, T ou NK (tipos de células de defesa), que foram infectadas pelo vírus Epstein-Barr. A forma como a doença se manifesta e sua gravidade dependem da imunidade da pessoa e de fatores do próprio vírus. A persistência viral nessas células pode causar desde um crescimento celular simples e reativo até tipos agressivos de câncer como linfomas e leucemias, cada um com características clínicas e patológicas únicas.

Medicamentos
4 registrados
BRENTUXIMAB VEDOTIN, PEMBROLIZUMAB, DOXORUBICIN HYDROCHLORIDE

Tem tratamento?

4 medicamentos registrados
Ver detalhes, fases e interações →
BRENTUXIMAB VEDOTINPEMBROLIZUMABDOXORUBICIN HYDROCHLORIDEVINBLASTINE SULFATE
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🩸
Sangue
12 sintomas
🫃
Digestivo
9 sintomas
🦴
Ossos e articulações
5 sintomas
🫁
Pulmão
3 sintomas
🛡️
Imunológico
2 sintomas
📏
Crescimento
2 sintomas

+ 20 sintomas em outras categorias

Características mais comuns

Linfoma de células B
Carcinoma de mama
Derrame pericárdico
Morfologia anormal do peritônio
Derrame pleural
Anormalidade do fígado
57sintomas
Sem dados (57)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 57 características clínicas mais associadas, ordenadas por frequência.

Linfoma de células BB-cell lymphoma
Carcinoma de mamaBreast carcinoma
Derrame pericárdicoPericardial effusion
Morfologia anormal do peritônioAbnormality of the peritoneum
Derrame pleuralPleural effusion

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa3
Últimos 10 anos200publicações
Pico2025133 papers
Linha do tempo
2023Hoje · 2026🧪 1990Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

2 genes identificados com associação a esta condição.

MYCMyc proto-oncogene proteinDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3' (PubMed:24940000, PubMed:25956029). Activates the transcription of growth-related genes (PubMed:24940000, PubMed:25956029). Binds to the VEGFA promoter, promoting VEGFA production and subsequent sprouting angiogenesis (PubMed:24940000, PubMed:25956029). Regulator of somatic reprogramming, controls self-renewal of embryonic stem cells (By similarity). Functions with TAF

LOCALIZAÇÃO

Nucleus, nucleoplasmNucleus, nucleolusNucleusCytoplasmChromosome

VIAS BIOLÓGICAS (10)
Cyclin A:Cdk2-associated events at S phase entryTranscription of E2F targets under negative control by DREAM complexCyclin E associated events during G1/S transition SMAD2/SMAD3:SMAD4 heterotrimer regulates transcriptionNOTCH1 Intracellular Domain Regulates Transcription
EXPRESSÃO TECIDUAL(Ubíquo)
Skin Not Sun Exposed Suprapubic
298.8 TPM
Fallopian Tube
238.6 TPM
Adipose Visceral Omentum
208.5 TPM
Linfócitos
195.3 TPM
Fibroblastos
193.2 TPM
OUTRAS DOENÇAS (3)
Burkitt lymphomaprecursor T-cell acute lymphoblastic leukemiahigh grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement
HGNC:7553UniProt:P01106
KLHDC8BKelch domain-containing protein 8BCandidate gene tested inTolerante
FUNÇÃO

Involved in pinching off the separated nuclei at the cleavage furrow and in cytokinesis (PubMed:20107318). Required for mitotic integrity and maintenance of chromosomal stability. Protects cells against mitotic errors, centrosomal amplification, micronucleus formation and aneuploidy. Plays a key role of midbody function involving abscission of the daughter cells during cytokinesis and appropriate chromosomal and nuclear segregation into the daughter cells (PubMed:22988245, PubMed:23713010)

LOCALIZAÇÃO

CytoplasmMidbody

MECANISMO DE DOENÇA

Lymphoma, Hodgkin, classic

A malignant disease characterized by progressive enlargement of the lymph nodes, spleen and general lymphoid tissue, and the presence of large, usually multinucleate, cells (Reed-Sternberg cells). Reed-Sternberg cells compose only 1-2% of the total tumor cell mass. The remainder is composed of a variety of reactive, mixed inflammatory cells consisting of lymphocytes, plasma cells, neutrophils, eosinophils and histiocytes.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
203.3 TPM
Ovário
200.7 TPM
Cólon sigmoide
134.6 TPM
Esôfago - Muscular
100.6 TPM
Esôfago - Junção
89.7 TPM
OUTRAS DOENÇAS (2)
nodular sclerosis classical Hodgkin lymphomaclassic Hodgkin lymphoma
HGNC:28557UniProt:Q8IXV7

Medicamentos e terapias

BRENTUXIMAB VEDOTINPhase 4

Mecanismo: Tubulin inhibitor

PEMBROLIZUMABPhase 4

Mecanismo: Programmed cell death protein 1 inhibitor

DOXORUBICIN HYDROCHLORIDEPhase 4

Mecanismo: DNA topoisomerase II alpha inhibitor

VINBLASTINE SULFATEPhase 4

Mecanismo: Tubulin inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

80 variantes patogênicas registradas no ClinVar.

🧬 MYC: GRCh37/hg19 8q24.13-24.3(chr8:126446968-146295771)x3 ()
🧬 MYC: NM_002467.6(MYC):c.31-11C>A ()
🧬 MYC: NM_002467.6(MYC):c.14G>A (p.Arg5Gln) ()
🧬 MYC: GRCh37/hg19 8q23.2-24.3(chr8:111432348-146295771)x3 ()
🧬 MYC: GRCh37/hg19 8q24.11-24.22(chr8:118071721-132774256)x1 ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado4
2Fase 22
1Fase 12
·Pré-clínico1
Medicamentos catalogadosEnsaios clínicos· 4 medicamentos · 5 ensaios
✓ Aprovados — podem ser usados hoje
BRENTUXIMAB VEDOTINPEMBROLIZUMABDOXORUBICIN HYDROCHLORIDEVINBLASTINE SULFATE
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doença linfoproliferativa associada a vírus Epstein-Barr

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

0 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
0 papers (10 anos)
#1

Molecular pathogenesis and evolving treatment landscape of extranodal NK/T-cell lymphoma.

Proceedings of the Japan Academy. Series B, Physical and biological sciences2026

Extranodal NK/T-cell lymphoma (ENKTL) is a rare, aggressive Epstein-Barr virus (EBV)-associated malignancy. The 5th edition of the WHO classification refined their nomenclature by removing "nasal type" and introducing related entities to reflect updated biological insights. This review synthesizes recent advances in epidemiology and molecular pathogenesis in ENKTL, highlighting recurrent driver gene alterations, particularly frequent mutations in X-linked genes such as DDX3X and MSN, alongside TP53 mutations and PD-L1 structural variations that facilitate immune evasion. We also discuss novel mouse models that replicate the ENKTL niche, revealing how Trp53 loss and the EBV oncoprotein LMP1 synergistically remodel the tumor microenvironment to promote lymphomagenesis. Therapeutically, while L-asparaginase-based regimens including SMILE and P-GemOx remain the standard of care, emerging immune checkpoint inhibitors have demonstrated encouraging efficacy, particularly in combination with chemotherapy. This review provides an integrated perspective on the evolving landscape of diagnosis, disease biology, and translational treatment strategies for NK/T-cell lymphoproliferative disorders.

#2

Epstein-Barr virus infection in children with liver transplantation.

World journal of hepatology2026 Feb 27

Epstein-Barr virus (EBV) infection commonly occurs in children, particularly in developing countries. Most children infected with EBV are asymptomatic, though some develop significant complications, including EBV-associated malignancies, hemophagocytic lymphohistiocytosis, and multiple sclerosis. In immunocompromised children, including those with liver transplantation, EBV infection manifests with a diverse spectrum of presentations, varying from asymptomatic to post-transplant lymphoproliferative disorder, which can evolve into lymphoma. Therefore, close monitoring, early detection, and prompt management are crucial. This review aimed to investigate the pathogenesis and manifestations of EBV in healthy children and those who underwent liver transplantation. The proposed algorithm for early EBV detection and management, along with case studies, is provided to help pediatricians increase their index of suspicion.

#3

Classic hodgkin lymphoma associated with Epstein-Barr virus reactivation during vedolizumab therapy for ulcerative colitis.

Clinical journal of gastroenterology2026 Feb 28

Epstein-Barr virus (EBV)-associated lymphoproliferative disorders have been reported in patients receiving immunosuppressive therapy for inflammatory bowel disease; however, the onset of classic Hodgkin lymphoma (cHL) during vedolizumab therapy is extremely rare. A 73 year-old woman with ulcerative colitis (UC) was steroid-dependent, showing disease exacerbation when prednisolone was tapered or discontinued. Azathioprine was administered eight years prior but was discontinued after a short period due to liver dysfunction. Vedolizumab was initiated 31 months before presentation. Despite initial improvements in UC with vedolizumab, hematochezia subsequently persisted. Other biologics or immunomodulators that could cause systemic immunosuppression were avoided because she was receiving treatment for breast cancer. Colonoscopy showed erosions in the transverse colon and an ulcerative lesion in the sigmoid colon. A biopsy revealed high-grade dysplasia in the transverse colon and inflammatory granulation tissue without malignancy in the sigmoid lesion; therefore, surgery was indicated. Laparoscopic total proctocolectomy was performed, and the surgical specimen contained Reed-Sternberg cells positive for CD20, CD30, PD-L1, and EBV-encoded RNA, establishing EBV-associated cHL. Although the development of cHL is likely multifactorial, clinicians should be aware that EBV-associated intestinal cHL may develop in patients with UC receiving vedolizumab when tumor-like ulcers or mural thickening are encountered.

#4

A multidimensional workflow profiling of allogeneic virus-specific T cell therapies reveals potency-linked signatures.

Nature communications2026 Jan 07

Allogeneic virus-specific T cell (VST) therapies offer distinct advantages, including scalability, rapid deployment, and manufacturing consistency, and have demonstrated efficacy in multiple clinical trials. However, identifying VST products with high therapeutic potential remains a major hurdle. Here, we present a multidimensional analytical platform that integrates in vitro and in vivo anti-viral reactivity, T cell receptor (TCR) repertoire analysis, gene expression profiling, immunophenotyping, and functional validation in a humanized mouse model. Epstein-Barr virus (EBV)-specific T cells expanded from HLA-diverse healthy donors consistently enriched for TCRs targeting EBV-encoded antigens. Transcriptomic and high-dimensional flow cytometric analyses revealed a distinct effector-associated signature. Importantly, this integrative approach uncovered correlative biomarkers of T cell potency and effector function, validated in an in vivo model of EBV-driven B cell lymphoma. These findings establish a scalable framework for the characterization of allogeneic T cell products and may inform the development of predictive metrics for in vivo efficacy.

#5

Withaferin A inhibits EBV-driven lymphomagenesis through multiple mechanisms, including EBNA1 degradation.

Blood2026 Feb 19

Epstein-Barr virus (EBV) infects over 90% of the global population and drives multiple aggressive B-cell malignancies, including Burkitt lymphoma, diffuse large B-cell lymphoma, and Hodgkin lymphoma. Standard chemoimmunotherapy regimens can be highly effective, yet Epstein-Barr virus positive (EBV+) lymphomas sometimes exhibit poorer responses, higher resistance, and worse survival compared with Epstein-Barr virus-negative (EBV-) counterparts. This reflects the virus's ability to drive immune evasion, alter cell death pathways, and exploit host immune dysfunction, underscoring the potential value of EBV-directed strategies. Withaferin A (WA), a steroidal lactone with known anticancer and anti-inflammatory properties, was evaluated for its efficacy against EBV-associated B-cell non-Hodgkin lymphomas (B-NHL). Across a panel of lymphoma cell lines, WA demonstrated selective cytotoxicity toward EBV+ B-NHL, in part through proteasome-dependent degradation of EBNA1 (EBV nuclear antigen 1) and subsequent loss of viral episomes, alongside additional effects on cellular stress and survival pathways. Mechanistic studies revealed that WA collapses antioxidant defenses, drives oxidative stress, and suppresses NF-κB signaling, creating a multipronged disruption of viral and host survival pathways. In primary B-cell models and a cord blood-humanized mouse model of EBV-driven lymphomagenesis, WA inhibited B-cell transformation, reduced splenomegaly and tumor burden, and significantly prolonged survival without evidence of increased viral replication. These findings establish WA as a potent preclinical candidate that selectively targets vulnerabilities unique to EBV-transformed B cells, supporting further optimization and evaluation for EBV+ B-cell malignancies.

Publicações recentes

Ver todas no PubMed

📚 EuropePMCmostrando 199

2026

[Clinical Characteristics and Prognostic Analysis of Patients with EBV-Positive Diffuse Large B-Cell Lymphoma].

Zhongguo shi yan xue ye xue za zhi
2026

[EBNA1 Knockdown Modulates Proliferation, Apoptosis, and Metabolism in Burkitt's Lymphoma Cells by Downregulating miR-127-5p].

Zhongguo shi yan xue ye xue za zhi
2026

A 43-Year-Old Man With Isolated Cutaneous Lymphomatoid Granulomatosis Presenting as a Chronic Necrotizing Ulcer of the Upper Arm.

The American journal of case reports
2026

Molecular pathogenesis and evolving treatment landscape of extranodal NK/T-cell lymphoma.

Proceedings of the Japan Academy. Series B, Physical and biological sciences
2026

Epstein-Barr virus infection in children with liver transplantation.

World journal of hepatology
2026

Composite lymphoma composed of follicular lymphoma and nodal T-follicular helper cell lymphoma: report of 3 cases highlighting histopathologic zonation of each neoplastic component.

American journal of clinical pathology
2026

Temporal association of diffuse large B-cell lymphoma with PD-1 inhibitor therapy in a patient with gastric adenocarcinoma: a case report.

Frontiers in immunology
2026

Classic hodgkin lymphoma associated with Epstein-Barr virus reactivation during vedolizumab therapy for ulcerative colitis.

Clinical journal of gastroenterology
2026

Expression of MicroRNA-155 and its associations with EBV serological markers and inflammatory cytokines in young lymphoma patients with evidence of active EBV infection.

Experimental biology and medicine (Maywood, N.J.)
2026

Inhibition of death-ligand-induced apoptosis in Epstein-Barr virus-encoded small RNAs-expressing human T-cell line.

Infectious agents and cancer
2026

Machine Learning Models for Posttransplant Lymphoproliferative Disorder (PTLD) Risk Prediction in Thoracic Transplantation.

ASAIO journal (American Society for Artificial Internal Organs : 1992)
2026

Rapidly Expanded EBV-Specific T Cells for the Treatment of Refractory EBV Reactivation and EBV-Related Lymphoproliferative Disorders.

Open forum infectious diseases
2026

Hemophagocytic lymphohistiocytosis associated with extranodal NK/T cell lymphoma, nasal type or aggressive NK cell leukemia: a retrospective multicenter study of Jiangsu Cooperative Lymphoma Group (JCLG).

Annals of hematology
2026

Pediatric lymphoproliferative disorders - Emerging insights and management: A narrative review.

Medicine
2026

Bilateral Breast Implant-Associated Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: A Case Report and Literature Review.

Annals of plastic surgery
2025

Autoimmune disease-associated lymphomas: research progress and review.

Frontiers in immunology
2026

Classical Hodgkin lymphoma associated with immune deficiency and dysregulation exhibits a prognosis similar to sporadic cases but with distinct predictive markers.

Annals of hematology
2026

Diagnostic challenges in Burkitt's lymphoma with skull base and paravertebral involvement, and hearing loss: a case report.

Journal of medical case reports
2026

Germline Homozygous RAG1 Missense Variant Associated With Epstein-Barr Virus Negative Childhood Burkitt Lymphoma: A Case Report.

Journal of pediatric hematology/oncology
2026

Epstein-Barr Virus-Associated T/NK-Cell Neoplasms.

Journal of medical virology
2026

Long-term trends of mortality from systemic lupus erythematosus in England & Wales and the United States.

Lupus
2026

A multidimensional workflow profiling of allogeneic virus-specific T cell therapies reveals potency-linked signatures.

Nature communications
2025

Higher chemical complementarity of EBV epitopes and IGH CDR3s correlates with better outcomes for lymphoma and ovarian cancer.

Cancer causes & control : CCC
2025

Dissecting Epstein-Barr Virus Dependence Across Diverse Infected Cell Models.

bioRxiv : the preprint server for biology
2026

Mantle cell lymphoma exhibiting repeated progression with the initiation of a JAK-1 inhibitor for psoriatic arthritis.

International journal of hematology
2025

Vitamin C conditioning generates tumor-targeting CAR T cells with superior cytotoxicity and fitness in a post-transplant lymphoproliferative disorder tumor model.

Molecular cancer therapeutics
2026

Dismal Outcome of EBV-Positive Nodal T/NK-Cell Lymphoma: A Multicenter Retrospective Study.

Clinical lymphoma, myeloma & leukemia
2026

Nodal T-follicular helper cell lymphoma with hodgkin/reed-sternberg-like cells: Clinicopathologic and molecular characterization of 11 cases.

Pathology, research and practice
2025

Histological subtypes of rheumatoid arthritis-associated lymphoproliferative disorders: Serological and Epstein-Barr virus findings.

Modern rheumatology
2026

Classic Hodgkin lymphoma in a patient with Behçet's disease: a case report and review of the literature.

Clinical rheumatology
2026

Redefining the Spectrum of Epstein-Barr Virus-Positive (EBV+) Diffuse Large B-cell Lymphoma and EBV+ Classic Hodgkin Lymphoma.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
2025

Epstein-Barr virus and human MiRNAs crosstalk: orchestrating latency, lytic cycle, and immune system modulation.

Folia microbiologica
2025

Epstein-Barr virus-associated lymphomas: biology, molecular genomics and precision oncology.

Frontiers in oncology
2025

Castleman Disease in a Child: A Rare Cause of Persistent Cervical Lymphadenopathy.

Cureus
2025

Impact of infection and microbial exposures on pediatric cancer.

Current problems in pediatric and adolescent health care
2025

EBV-Positive Diffuse Large B-Cell Lymphoma (DLBCL): An Assessment and a Roadmap.

Journal of medical virology
2025

HIV-associated non-Hodgkin lymphoma tumor-microenvironment axes differ by EBV status across cellular origins.

bioRxiv : the preprint server for biology
2025

Active Epstein-Barr virus infection and its association with multiple myeloma: evidence from a meta-analytical perspective.

Hematology (Amsterdam, Netherlands)
2025

Epstein-barr virus-encoded small RNA incorporated prognostic model enables precision risk stratification and guides treatment decisions in peripheral t-cell lymphoma: a multicenter retrospective cohort.

Annals of hematology
2025

Recent advances in infections as risk factors for lymphoma: a review of the effects of viral, bacterial, and fungal infections in lymphoma.

Archives of microbiology
2025

Monocyte/macrophages may exert prominent roles in macrophage activation syndrome.

Annals of hematology
2025

[Late-onset Epstein-Barr virus-positive diffuse large B-cell lymphoma at the same site after treatment of extranodal NK/T-cell lymphoma].

[Rinsho ketsueki] The Japanese journal of clinical hematology
2025

Lysine-specific histone demethylase complex restricts Epstein-Barr virus lytic reactivation.

Nature microbiology
2026

Primary Cutaneous B-Cell Lymphomas: An Updated Portrait of Classification, Biology, and Clinical Management.

European journal of haematology
2025

[Primary cutaneous B-cell lymphomas-an overview of established and novel aspects].

Dermatologie (Heidelberg, Germany)
2025

Epstein-Barr Virus-Positive Lymphoproliferative Disorder in an HIV Patient Successfully Treated With Rituximab.

Cureus
2025

LMP2A-Targeting CAR-T Cells Equipped With Inducible IL-18 to Address EBV-Associated Malignancies.

HLA
2026

Withaferin A inhibits EBV-driven lymphomagenesis through multiple mechanisms, including EBNA1 degradation.

Blood
2025

Burkitt in disguise: clonal transformation of incidentally detected gallbladder diffuse large B-cell lymphoma in a liver transplant recipient.

International journal of hematology
2025

Oral Plasmablastic Lymphoma: Case Series and Literature Review.

Head & neck
2025

Primary intracranial plasmablastic lymphoma with intradural extramedullary metastasis: a case report.

BMC neurology
2025

Exploring the Potential Association of Infectious Mononucleosis With Diffuse Large B-Cell Lymphoma: A Mendelian Randomization and miRNA Profiling Approach.

Journal of medical virology
2025

The pathogenic role and genomic characteristics of Epstein-Barr virus in vitreoretinal lymphoma.

Virologica Sinica
2025

Aflatoxin B1 induces subtle but coordinated histone modifications in Epstein-Barr virus infected and non-infected Burkitt lymphoma cells.

Environment international
2025

Diagnostic Challenges in Diffuse Large B-Cell Lymphoma in a Young Liver Transplant Patient with Ulcerative Colitis: A Case Report.

The American journal of case reports
2026

The incidence and role of EBV and HIV in head and neck lymphomas: an institutional study.

Oral surgery, oral medicine, oral pathology and oral radiology
2025

Pediatric Liver Transplant Complications: EBV-Associated Tumors and Infection Management Strategies.

The American journal of case reports
2025

[Monomorphic epitheliotropic intestinal T-cell lymphoma: a clinicopathological and genetic mutation characteristics analysis of forty-two cases].

Zhonghua bing li xue za zhi = Chinese journal of pathology
2025

[New advances in the pathology and diagnostic challenges of extranodal NK/T-cell lymphoma].

Zhonghua bing li xue za zhi = Chinese journal of pathology
2025

[Current status and challenges of AIDS-related malignant lymphoma].

[Rinsho ketsueki] The Japanese journal of clinical hematology
2025

Methotrexate-Associated Primary Cutaneous Epstein-Barr Virus-Positive Polymorphic B-Cell Lymphoproliferative Disorder With Metachronous T-Cell Clonally Related Angioimmunoblastic T-Cell Lymphoma: A Case Report and Review of the Literature.

The American Journal of dermatopathology
2025

The clinical features and outcomes of aggressive large B cell lymphoma with concomitant hemophagocytic lymphohistiocytosis at diagnosis.

Annals of hematology
2025

CD20-Negative Large B-Cell Lymphomas: The Diagnostic Challenge of Tumors with Downregulation of Mature B-Cell Marker Expression.

International journal of molecular sciences
2025

Follicular Helper T-Cell Lymphomas With Epstein-Barr Virus-Positive Neoplastic Cells: A Rare Scenario With Diagnostic Implications.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
2025

Long-Term Efficacy of Epstein-Barr Virus-Specific T Cells for Epstein-Barr Virus-Associated Post-Transplantation Lymphoproliferative Disorder after Allogeneic Stem Cell Transplantation: A Real-World Study.

Transplantation and cellular therapy
2025

Belatacept and non-melanoma skin cancer risk in kidney transplant recipients: a narrative review from a mechanistic and clinical perspective.

BMC nephrology
2025

Clinical and functional characterization of a novel TNFRSF9 variant causing immune dysregulation with predisposition to EBV-driven lymphomagenesis.

Frontiers in immunology
2025

Incidence and outcomes of post-transplant lymphoproliferative disorder in the Western Australian liver transplant population: a 24-year retrospective study.

Internal medicine journal
2025

Peripheral EBV antigen-specific T cell is dysfunctional in Epstein-Barr virus positive diffuse large B-cell lymphoma.

BMC cancer
2025

Clinical Significance of Plasma and Peripheral Blood Mononuclear Cell EBV-DNA in Lymphoma.

Journal of clinical laboratory analysis
2025

Primary Immunodeficiencies and EBV-Associated Diseases.

Current topics in microbiology and immunology
2025

ASXL1 deficiency causes epigenetic dysfunction, combined immunodeficiency, and EBV-associated lymphoma.

The Journal of experimental medicine
2025

Current State of AIDS-Related Malignant Lymphoma.

Viruses
2025

Clinical characteristics and prognosis of EBV-Positive mature B-Cell lymphoma in children: a retrospective study.

Annals of hematology
2025

The expanding spectrum of T-cell lymphomas with follicular helper T-cell phenotype and implications for differential diagnoses: A report of the 2023 SH/EA4HP Lymphoma Workshop.

American journal of clinical pathology
2025

A genome-wide association study identifies an African-specific locus on chromosome 21q22.12 associated with Burkitt lymphoma risk and survival.

Leukemia
2025

Exploring the Genetic Landscape of Primary Marginal Zone Lymphoma of the Urinary Bladder.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
2025

Case Report: dose adjustment of orelabrutinib for managing central nervous system post-transplant lymphoproliferative disorder following acute lymphoblastic leukemia transplantation.

Frontiers in immunology
2025

Crescentic glomerulonephritis associated with NK-large granular lymphocytic leukemia: A case report.

Medicine
2025

Epstein-Barr virus-infected tonsillar marginal zone B cells in vivo as a precursor for immunosuppression-related B-cell lymphoma.

Journal of virology
2025

PARP1 Inhibition Halts EBV+ Lymphoma Progression by Disrupting the EBNA2/MYC Axis.

Journal of medical virology
2025

Epstein-Barr virus-positive T- and NK-cell lymphoproliferative disorders: Report from the 2023 SH/EA4HP Lymphoma Workshop.

American journal of clinical pathology
2025

Epstein Barr virus antibody and cancer risk in two prospective cohorts in Southern China.

Nature communications
2025

Plasmablastic Lymphoma-A Crosstalk Between Myeloma and Lymphoma.

Clinical lymphoma, myeloma & leukemia
2025

TCF3 and ID3 Regulate TSPAN32 Expression in Burkitt Lymphoma.

Scandinavian journal of immunology
2025

Association of Epstein-Barr virus genomic alterations with human pathologies.

Blood
2025

High PD-L1 Expression in HRS Cells and Macrophages in Tumor Immune Microenvironment Is Associated with Adverse Outcome and EBV Positivity in Classical Hodgkin Lymphoma.

International journal of molecular sciences
2025

Protracted Tonsillitis as an Atypical Initial Manifestation of Methotrexate-Induced EBV-Positive Lymphoproliferative Disorder in Rheumatoid Arthritis: A Case Report and Literature Review.

Diagnostics (Basel, Switzerland)
2025

Kaposi sarcoma-associated herpesvirus cooperates with Epstein-Barr virus to co-transform a small set of human B cells oncogenically.

PLoS pathogens
2025

Imaging of Immunodeficiency-Associated Lymphoproliferative Disorders.

Seminars in ultrasound, CT, and MR
2026

Methotrexate-associated Angioimmunoblastic T-cell Lymphoma Presenting with Acute Kidney Injury.

Internal medicine (Tokyo, Japan)
2025

Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T-Cell Lymphoma.

American journal of hematology
2025

[Methotrexate-related lymphoproliferative disease of the ileum with fistular formation between the small bowel and rectum:a case report].

Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
2025

Extramedullary plasmacytoma in children is a genetically distinct localized neoplasia curable by surgical resection.

Blood advances
2025

Tumor-Associated Sympathetic Nerves Promote the Progression of Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
2025

Prophylactic and Therapeutic EBV Vaccination.

Current topics in microbiology and immunology
2025

Efficacy and prognosis of allogeneic hematopoietic stem cell transplantation in aggressive NK-cell leukemia: a meta-analysis.

Annals of hematology
2025

Differential expression of proliferation and immune response genes between children and adults influences survival of diffuse large B cell lymphoma.

Scientific reports
2025

Genetic Profiling Reveals the Distinctions Among MTX-Associated DLBCL, EBV-Positive Mucocutaneous Ulcer, and EBV + DLBCL.

Cancer science
2025

Clinicopathological features and prognostic factors of AIDS-related lymphoma: a retrospective single-center study in China.

Annals of hematology
2025

Internalization of extracellular double-stranded DNA as a potential marker of cancer stem cells in Epstein-Barr virus-induced B-cell lymphoma.

Cancer biomarkers : section A of Disease markers
2025

Epstein-Barr virus-associated infectious mononucleosis exhibits substantially higher non-treponemal test titers in biological false-positive reactions.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
2025

EBV-positive diffuse large B cell lymphoma secondary to activated phosphoinositide 3 kinase δ syndrome type 1 (APDS1): a case report and literature review.

Frontiers in immunology
2025

Harnessing Cellular Immunotherapy for EBV-Associated Malignancies: Current Advances and Future Directions.

Journal of cellular and molecular medicine
2025

Targeting intracellular LMP2 with costimulatory signal-armed antibody-like TCR T cells.

JCI insight
2025

Epstein-Barr virus latent membrane protein 1 subverts IMPDH pathways to drive B-cell oncometabolism.

PLoS pathogens
2025

MicroRNA changes with macro potential contribute to secondary immunodeficiency in chronic lymphocytic leukemia during epstein barr virus reactivation.

Scientific reports
2025

STAT3, MYC, and EBNA1 cooperate through a ZC3H18 transcriptional network to regulate survival and proliferation of EBV-positive lymphomas.

PLoS pathogens
2025

DNA Methylation Epitypes of Burkitt Lymphoma with Distinct Molecular and Clinical Features.

Blood cancer discovery
2025

Spatial transcriptomics reveals tumor microenvironment heterogeneity in EBV positive diffuse large B cell lymphoma.

Scientific reports
2025

Leveraging the interconnected unfolded protein response and NLRP3 inflammasome pathways to reactivate Epstein-Barr virus in diffuse large B-cell lymphomas.

NAR cancer
2025

Integration of anti-PD-1 antibody into chemotherapeutic regimens improved the outcome of aggressive NK cell leukemia: a single-center retrospective real-world analysis.

Frontiers in immunology
2025

Systemic EBV+ T-Cell Lymphoma of Childhood with Hemophagocytic Lymphohistiocytosis in a Patient with a Highly Complex Karyotype.

Genes
2025

Human Immune Responses to Epstein-Barr Virus Highlighted by Immunodeficiencies.

Annual review of immunology
2025

Understanding EBV infection and EBV-associated lymphomas in children.

Virology
2025

Long-term outcomes in patients with persistent EBV-DNA positivity after primary Epstein-Barr virus infection and clinical implications of rituximab therapy.

International immunopharmacology
2025

Concomitant Splenic Tuberculosis and Epstein-Barr Virus-Related T-Cell Leukemia/Lymphoma in a 28-Year-Old Pregnant Woman in South Sudan.

The American journal of tropical medicine and hygiene
2025

Cytogenomic and Clinicopathologic Comparison of MYC-Positive and MYC-Negative High-Grade B-Cell Lymphoma With 11q Aberration in the Context of Other Aggressive Lymphomas With MYC Rearrangement.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
2025

Fibrin-associated large B-cell lymphoma arising in a cystic lymphangiomatous lesion of the adrenal gland: A case report and overview of the entity.

Pathology, research and practice
2025

Plasmablastic lymphoma with cutaneous manifestations in an immunocompetent man: A rare case report with literature review.

Journal of cancer research and therapeutics
2025

Subtyping Burkitt Lymphoma by DNA Methylation.

Genes, chromosomes & cancer
2025

Comparison of nanopore with illumina whole genome assemblies of the Epstein-Barr virus in Burkitt lymphoma.

Scientific reports
2025

[Clinicopathological features and prognostic value of CD30 expression in EBV-positive diffuse large B cell lymphoma].

Zhonghua bing li xue za zhi = Chinese journal of pathology
2025

A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities.

Cell reports. Medicine
2025

Recent advances in animal models of lymphomagenesis caused by human γ-herpesviruses.

Current opinion in virology
2025

Pandemic-Driven Shifts in Epstein-Barr Virus (EBV) Epidemiology: Single Center Study.

Viruses
2025

Burkitt lymphoma in patients with chronic lymphocytic leukemia and other indolent B-cell lymphoid malignancies.

Leukemia & lymphoma
2025

Prognostic impact of pre-treatment and post-treatment plasma Epstein-Barr virus DNA in peripheral T-cell lymphomas.

Annals of medicine
2025

HIV-negative primary effusion lymphoma: a series of seven cases.

Histopathology
2025

Does CD47 expression have prognostic significance in classical Hodgkin lymphoma?

Turkish journal of medical sciences
2025

Real-world evidence regarding cancer, mortality, and graft failure risk with de novo belatacept use among kidney transplant recipients in the United States.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
2026

Large B-cell lymphoma associated with fluid overload: two new case reports with molecular insights.

Virchows Archiv : an international journal of pathology
2025

Incorporation of Epstein-Barr viral variation implicates significance of Latent Membrane Protein 1 in survival prediction and prognostic subgrouping in Burkitt lymphoma.

International journal of cancer
2025

Development and validation of a predictive model for diagnosing EBER-positive lymphoma-associated hemophagocytic lymphohistiocytosis.

BMC cancer
2025

Navigating Epstein-Barr Virus (EBV) and Post-Transplant Lymphoproliferative Disorder (PTLD) in Pediatric Liver Transplantation: Current Knowledge and Strategies for Treatment and Surveillance.

Viruses
2025

Genetic evidence identifies a causal relationship between EBV infection and multiple myeloma risk.

Scientific reports
2025

PD-L1/PD-L2 genetic profile in the molecular cytogenetic classification of classic Hodgkin lymphoma.

Virchows Archiv : an international journal of pathology
2025

Development of a novel prognostic nomogram for AIDS-associated diffuse large B-cell lymphoma: a retrospective study from northern China.

Clinical and experimental medicine
2025

Gp350-targeted CAR-T therapy in EBV-positive Burkitt lymphoma: pre-clinical development of gp350 CAR-T.

Journal of translational medicine
2024

Age-related immunosenescence and Epstein-Barr virus-positive mucocutaneous ulcer presenting as oral cancer: a case report.

Frontiers in medicine
2025

Epstein-Barr Virus-Encoded Latent Membrane Protein 2A Promotes Immune Escape by Upregulating SYK/Nuclear Factor-κB Signaling in Diffuse Large B-cell Lymphoma.

Laboratory investigation; a journal of technical methods and pathology
2025

Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas.

Blood advances
2025

Classic Hodgkin lymphoma: Pathobiological features that impact emerging therapies.

Blood reviews
2025

Risk and prognosis of posttransplant lymphoproliferative disease in Epstein-Barr virus-seronegative kidney transplant recipients - an observational cohort study from Norway and western Denmark.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
2025

Computational pathology identifies a low B-cell content in the tumour microenvironment as a predictor of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD.

Journal of clinical pathology
2025

Better Outcomes for Ovarian Cancer Associated With the Detection of Anti-EBV TCR CDR3s: Potential Relevance to Diffuse Large B-Cell Lymphoma.

American journal of reproductive immunology (New York, N.Y. : 1989)
2025

Topological importance of CD8+ T-cell enrichment in the tumor microenvironment of classic Hodgkin lymphoma.

Annals of hematology
2025

Clinical, Pathologic, and Molecular spectrum of Angioinmmunoblastic T-cell Lymphoma Cutaneous Lesions: Clinical, Pathologic, and Molecular Analysis.

The American journal of surgical pathology
2025

Targeted Next-Generation Sequencing of Cell-Free DNA to Detect MYC-Immunoglobulin Translocation and Epstein-Barr Virus DNA in Plasma of Burkitt Lymphoma Patients in East Africa.

JCO global oncology
2025

Rare Cutaneous Primary Presentation of Extracavitary Primary Effusion Lymphoma.

The American Journal of dermatopathology
2025

RASGRP1 Deficiency Associated with Diffuse Mesangial Sclerosis Infantile Nephrotic Syndrome and Epstein-Barr Virus-Induced Hodgkin's Lymphoma.

Pediatric allergy, immunology, and pulmonology
2025

Primary thyroid B-cell lymphoma: molecular insights into its clonal evolution and relapse.

The Journal of pathology
2025

Epstein-Barr virus-associated lymphoproliferative disease during remission after induction therapy with dasatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a case report.

Annals of hematology
2024

Spontaneous Regression of Plasmablastic Lymphoma Associated With Methotrexate After Withdrawal.

Journal of hematology
2024

Role of rapidly evolving immunotherapy in chronic active Epstein-Barr virus disease.

Frontiers in immunology
2024

Atypical presentations of primary lymphoproliferative processes in the central nervous system.

Radiologia
2024

Multi-modal analysis reveals tumor and immune features distinguishing EBV-positive and EBV-negative post-transplant lymphoproliferative disorders.

Cell reports. Medicine
2024

Transmission of an Epstein-Barr Strain Common in South-East China to a Western Individual.

Journal of medical virology
2024

EBV and post-transplant lymphoproliferative disorder: a complex relationship.

Hematology. American Society of Hematology. Education Program
2025

From the archives of MD Anderson Cancer Center: EBV-positive fibrin-associated large B-cell lymphoma in an ovarian leiomyoma with cystic degeneration: A case report and discussion of differential diagnosis.

Annals of diagnostic pathology
2024

Decoding Critical Targets and Signaling Pathways in EBV-Mediated Diseases Using Large Language Models.

Viruses
2024

Hodgkin lymphoma: the role of EBV plasma viral load testing in an HIV-endemic setting.

Clinical and experimental medicine
2025

Distinct epigenetic and transcriptional profiles of Epstein-Barr virus-positive and negative primary CNS lymphomas.

Neuro-oncology
2025

Epstein-Barr virus-associated B-cell lymphoproliferative disorders and lymphomas: Diagnostic overlaps and defining features.

Human pathology
2024

Posttransplant Lymphoproliferative Disorder in Pediatric Solid-Organ Transplant Recipients: A 7-Year Single-Center Analysis.

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
2024

Ubiquitin-Mediated Effects on Oncogenesis during EBV and KSHV Infection.

Viruses
2025

Genetic and immunological features of immune deficiency and dysregulation-associated lymphoproliferations and lymphomas as a basis for classification.

Histopathology
2025

Lymphoproliferative Disorder in an Esophageal Cancer Patient Treated with Pembrolizumab.

Internal medicine (Tokyo, Japan)
2024

The role of c-Myc in Epstein-Barr virus-associated cancers: Mechanistic insights and therapeutic implications.

Microbial pathogenesis
2025

B Cell Differentiation and the Origin and Pathogenesis of Human B Cell Lymphomas.

Methods in molecular biology (Clifton, N.J.)
2024

Hemophagocytic lymphohistiocytosis in a patient with Epstein-Barr virus-positive diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.

Immunotherapy
2025

Nodal T-Cell Lymphoma Transdifferentiated from Mantle Cell Lymphoma with Epstein-Barr Virus Infection.

Pathobiology : journal of immunopathology, molecular and cellular biology
2025

Detection of anti-EBV TCR CDR3s associated with better outcomes for EBV-positive, Ugandan cases of Burkitt lymphoma.

International journal of cancer
2024

Fibrin associated large B-cell lymphoma accidentally identified in a breast implant capsule: a molecular report of a rare entity.

Pathologica
2025

Breast Implant-Related EBV + Diffuse Large B-Cell Lymphoma-Case Report and Review of the Literature.

International journal of surgical pathology
2024

Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2024

Epstein-Barr virus-positive plasmacytoma in an immunocompetent female: A case report.

Journal of clinical and experimental hematopathology : JCEH
2024

Epstein-Barr virus-related lymphoproliferative disorders of the skin.

Dermatology reports
2024

Post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation: a case report, meta-analysis, and systematic review.

Diagnostic pathology
2024

The DNA loop release factor WAPL suppresses Epstein-Barr virus latent membrane protein expression to maintain the highly restricted latency I program.

PLoS pathogens
2024

Adult T-cell leukemia/lymphoma with angioimmunoblastic T-cell lymphoma-like feature and molecularly confirmed RHOA Gly 17 Val (G17V) mutation: A case report.

Pathology international
2025

Oral manifestations of peripheral T cell lymphoma, not otherwise specified: case series and review of the current literature.

Oral surgery, oral medicine, oral pathology and oral radiology
2024

XMEN-associated Systemic EBV-positive T-cell Lymphoma of Childhood: Report of Two Cases and Literature Review.

Journal of pediatric hematology/oncology
2024

Systemic EBV-positive T-cell lymphoma of childhood with unusual cytogenetic findings and family history of Still's disease-associated recurrent macrophage activation syndrome.

Pediatric blood & cancer
2024

Stem cell memory EBV-specific T cells control EBV tumor growth and persist in vivo.

Science advances
2024

Resistance mechanisms and potential therapeutic strategies in relapsed or refractory natural killer/T cell lymphoma.

Chinese medical journal
2024

Clinicopathological and Molecular Characteristics of Rare EBV-associated Diffuse Large B-cell Lymphoma With IRF4 Rearrangement.

The American journal of surgical pathology
2024

Mechanistic Understanding of EBV+Lymphoproliferative Disease Development After Transplantation.

Transplantation
2025

Clinicopathologic Insights and Molecular Oncogenesis: Understanding Epstein-Barr Virus-Induced B-cell Lymphoproliferations.

International journal of surgical pathology
2024

LMP1 enhances aerobic glycolysis in natural killer/T cell lymphoma.

Cell death & disease
2024

Enhancing diagnostic precision in EBV-related HLH: a multifaceted approach using 18F-FDG PET/CT and nomogram integration.

Cancer imaging : the official publication of the International Cancer Imaging Society
2024

Epstein-Barr Virus-Associated Smooth Muscle Tumor After Kidney Transplantation: A French Multicenter Retrospective Study.

Clinical transplantation
2024

HIV infection is associated with compromised tumor microenvironment adaptive immune reactivity in Hodgkin lymphoma.

Blood advances
2024

Enhanced prognostic evaluation of diffuse large B-cell lymphoma: A comprehensive surveillance study incorporating Epstein-Barr virus infection status and immunohistochemical markers.

Journal of medical virology
2024

Combined Flow-Fluorescence in situ hybridization to HHV-8 and EBV reveals the viral heterogeneity of primary effusion lymphoma.

Journal of medical virology
2024

Epstein-Barr virus-driven lymphoproliferation in inborn errors of immunity: a diagnostic and therapeutic challenge.

Expert review of clinical immunology
2024

Impact of prophylaxis with rituximab on EBV-related complications after allogeneic hematopoietic cell transplantation in children.

Frontiers in immunology
2024

A proteome-wide analysis unveils a core Epstein-Barr virus antibody signature of classic Hodgkin lymphoma across ethnically diverse populations.

International journal of cancer
2023

Post-transplant lymphoproliferative disorder risk and outcomes in renal transplant patients treated with belatacept immunosuppression.

Frontiers in transplantation

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doença linfoproliferativa associada a vírus Epstein-Barr.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Doença linfoproliferativa associada a vírus Epstein-Barr

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Molecular pathogenesis and evolving treatment landscape of extranodal NK/T-cell lymphoma.
    Proceedings of the Japan Academy. Series B, Physical and biological sciences· 2026· PMID 41813156mais citado
  2. Epstein-Barr virus infection in children with liver transplantation.
    World journal of hepatology· 2026· PMID 41809485mais citado
  3. Classic hodgkin lymphoma associated with Epstein-Barr virus reactivation during vedolizumab therapy for ulcerative colitis.
    Clinical journal of gastroenterology· 2026· PMID 41762376mais citado
  4. A multidimensional workflow profiling of allogeneic virus-specific T cell therapies reveals potency-linked signatures.
    Nature communications· 2026· PMID 41495027mais citado
  5. Withaferin A inhibits EBV-driven lymphomagenesis through multiple mechanisms, including EBNA1 degradation.
    Blood· 2026· PMID 41105850mais citado
  6. [Clinical Characteristics and Prognostic Analysis of Patients with EBV-Positive Diffuse Large B-Cell Lymphoma].
    Zhongguo Shi Yan Xue Ye Xue Za Zhi· 2026· PMID 41846339recente
  7. [EBNA1 Knockdown Modulates Proliferation, Apoptosis, and Metabolism in Burkitt's Lymphoma Cells by Downregulating miR-127-5p].
    Zhongguo Shi Yan Xue Ye Xue Za Zhi· 2026· PMID 41846335recente
  8. A 43-Year-Old Man With Isolated Cutaneous Lymphomatoid Granulomatosis Presenting as a Chronic Necrotizing Ulcer of the Upper Arm.
    Am J Case Rep· 2026· PMID 41831228recente
  9. Composite lymphoma composed of follicular lymphoma and nodal T-follicular helper cell lymphoma: report of 3 cases highlighting histopathologic zonation of each neoplastic component.
    Am J Clin Pathol· 2026· PMID 41786658recente
  10. Temporal association of diffuse large B-cell lymphoma with PD-1 inhibitor therapy in a patient with gastric adenocarcinoma: a case report.
    Front Immunol· 2026· PMID 41766867recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:289644(Orphanet)
  2. MONDO:0017343(MONDO)
  3. GARD:21147(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q55786997(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Doença linfoproliferativa associada a vírus Epstein-Barr
Compêndio · Raras BR

Doença linfoproliferativa associada a vírus Epstein-Barr

ORPHA:289644 · MONDO:0017343
Medicamentos
4 registrados
MedGen
UMLS
C2363744
Wikidata
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades